Dr. Heather-Marie Schmidt: WHO Long-Acting PrEP Guidelines and Priority Actions to End HIV Epidemic in Asia  

Dr. Heather-Marie Schmidt: WHO Long-Acting PrEP Guidelines and Priority Actions to End HIV Epidemic in Asia  

Heather-Marie Schmidt BMedSc (Hon), MPH, PhD Dr. Schmidt serves as the Regional Advisor on HIV Testing, Prevention, and Key Populations for the Joint United Nations Programme on HIV/AIDS (UNAIDS) Asia-Pacific Regional Office and the World Health Organization (WHO) Global HIV, Hepatitis, and Sexually Transmitted Infections Program. She is dedicated to developing global guidelines for PrEP (Pre-Exposure Prophylaxis) and PEP (Post-Exposure Prophylaxis) and providing technical assistance to countries, organizations, and communities in the Asia-Pacific region to support the implementation and promotion of PrEP.
Dr. Jennifer Hoy: How to Safely Transition ART in HIV Patients Achieving Viral Suppression?

Dr. Jennifer Hoy: How to Safely Transition ART in HIV Patients Achieving Viral Suppression?

Infectious Disease/HIV Specialist and Medical Professor at Monash University Alfred Hospital, Australia. Member of the Australian Antiretroviral Guidelines Committee and the International Antiviral Society-USA (IAS-USA) Antiretroviral Guidelines Panel. Leading and participating in the development of new antiretroviral drugs and the prevention and management of opportunistic infections, with a primary research focus on complications related to aging in HIV-infected individuals and their pathogenesis, prevention, and management.
Dr. Dong Xu: Meeting More Patient Needs in HIV Health Management

Dr. Dong Xu: Meeting More Patient Needs in HIV Health Management

Implementation Science is a relatively new and increasingly recognized field of research. Its purpose is to translate the possibilities outlined in theory into practical applications in the real world, addressing the challenges of implementing validated intervention measures. At the 2023 APACC conference, Dr. Dong Hsu, from the School of Public Health Management and the Global Health Research Center, Southern Medical University, China, delivered an insightful presentation titled "Implementation of Clinical Practice Guidelines". In our interview, Dr. Dong Hsu further elaborated on the definition and research value of Implementation Science and shared his team's research findings in areas such as HIV screening and health management.
Dr. Lang Bai: The Impact and Mechanism of TmPV1 Fungivirus on Talaromyces Marneffei Virulence

Dr. Lang Bai: The Impact and Mechanism of TmPV1 Fungivirus on Talaromyces Marneffei Virulence

Over the years, significant progress has been made in the prevention and treatment of HIV/AIDS and co-infections. Society has provided the best medications and professional knowledge to combat HIV infections, making substantial contributions to those affected. From June 8th to 10th, 2023, the Asia-Pacific AIDS and Co-Infections Conference (APACC 2023) was held in Singapore. In this issue, we are honored to invite Dr. Lang Bai, Deputy Director of the Infectious Diseases Center, West China Hospital, Sichuan University, China, to share with us the latest research on Talaromyces marneffei infection, a common fungal disease among AIDS patients and other immunocompromised individuals in Southeast Asia.
Dr. Peter Reiss: Moving Towards the Fourth “90” Goal – Strategies for Improving the Quality of Life and Management of HIV/AIDS Patients

Dr. Peter Reiss: Moving Towards the Fourth “90” Goal – Strategies for Improving the Quality of Life and Management of HIV/AIDS Patients

Honorary Dr. at the Amsterdam University Medical Center, University of Amsterdam, former President of the European AIDS Clinical Society (EACS) (2008-2012), former Regional Director for Europe and Central Asia on the Governing Council of the International AIDS Society (IAS) (2006-2014), Co-Chair of the 22nd International AIDS Conference (AIDS 2018), Director of the Netherlands HIV Monitoring Foundation, member of the National Institutes of Health/National Institute of Allergy and Infectious Diseases (NIH/NAID) HIV Vaccine Data and Safety Monitoring Board, and member of various committees including CROI, EACS, and HIV Glasgow. At the APACC 2023 conference, Dr. Peter Reiss was invited to give keynote speeches in several specialized sessions and also presented the "Lifetime Achievement Award" at the conference. Following Dr. Reiss's insightful presentation on "Improving the Quality of Life for HIV/AIDS Patients," our publication's reporter conducted an in-depth interview with him at the conference venue.
Dr. Linghua Li: Breakthrough on Hepatitis B Cure in HIV/HBV Co-Infected Patients

Dr. Linghua Li: Breakthrough on Hepatitis B Cure in HIV/HBV Co-Infected Patients

The 8th Asia-Pacific AIDS and Co-infection Conference (APACC 2023) was held in Singapore from June 8 to 10, 2023. During this conference, an oral presentation (Abstract #9) conducted by Dr. Linghua Li's team from the Eighth Affiliated Hospital, Guangzhou Medical University, China, attracted significant attention. Dr. Li 's team, based on the latest findings from a large cohort study, revealed that the hepatitis B surface antigen (HBsAg) clearance rate in HIV/HBV co-infected individuals who received long-term combination antiretroviral therapy (cART) could reach 8.1%. Furthermore, the research results unveiled that the main influencing factors for HBsAg clearance in HIV/HBV co-infected individuals included low baseline HBsAg levels, HBV genotype B, and a more than two-fold increase in ALT within six months of treatment.
Youth Forum of APACC 2023  | (5R)-5-hydroxytriptolide Holds Promise for HIV immunological Non-responders Receiving ART

Youth Forum of APACC 2023  | (5R)-5-hydroxytriptolide Holds Promise for HIV immunological Non-responders Receiving ART

Hello everyone, I'm Xiaosheng Liu , a graduate student from Professor Taisheng Li's team of Peking Union Medical College Hospital, China. My primary research focus is on the mechanisms underlying immunological non-response in HIV/AIDS patients after long-term antiviral therapy and the development of therapeutic drugs for this condition. I'm delighted to participate in this year's APACC conference (2023) and present two poster studies conducted by our team at the conference. APACC is the most cutting-edge and top academic conference in the Asia-Pacific region for HIV/AIDS, and I hope to broaden my knowledge in various aspects through this conference.
Dr. Deborah Donnell: A new long-acting PrEP regimen holds promise to transform the landscape of HIV prevention.

Dr. Deborah Donnell: A new long-acting PrEP regimen holds promise to transform the landscape of HIV prevention.

In 2021, the United Nations set forth the goal of "ending the AIDS epidemic by 2030". To achieve this, not only must countries strengthen the diagnosis and treatment of HIV infections, but they also need to prioritize prevention to minimize the emergence of new infections. Pre-Exposure Prophylaxis (PrEP) long-acting regimens have become a recent focal point in HIV prevention. At the recently held 12th International AIDS Society HIV Science Conference (IAS 2023), there were several keynote lectures on the topic of long-acting PrEP. Infectious Disease Frontier had the privilege to interview Dr. Deborah Donnell from the Vaccine and Infectious Disease Division of the Fred Hutchinson Cancer Research Center at the University of Washington, who shared her insights on the challenges faced in HIV prevention and the characteristics of the new long-acting PrEP regimen.
IAS 2023 | What are the sequelae of MPOX? Does HIV increase the risk of hospitalization due to MPOX?

IAS 2023 | What are the sequelae of MPOX? Does HIV increase the risk of hospitalization due to MPOX?

The 12th International AIDS Association HIV Science Conference (IAS 2023) was held in Brisbane, Australia from July 23 to 26, 2023. In the oral reports of the conference, experts from the World Health Organization (WHO) reported that global monitoring data for MPOX in 2022 showed that half of the patients with MPOX were HIV carriers. However, HIV is not a risk factor for increased hospitalization due to MPOX. Another study based on interviews with MPOX patients in Australia indicated that most patients had negative experiences with the disease and sequelae related to MPOX.